Bannerji, R., Arnason, J. E., Advani, R. H., Brown, J. R., Allan, J. N., Ansell, S. M., Barnes, J. A., O'Brien, S. M., Chávez, J. C., Duell, J., Rosenwald, A., Crombie, J. L., Ufkin, M., Li, J., Zhu, M., Ambati, S. R., Chaudhry, A., Lowy, I., & Topp, M. S. (2022). odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet, 9(5), e327–e339. http://access.bl.uk/ark:/81055/vdc_100153807955.0x000009